- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04719585
Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: RCT
Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: Randomized Controlled Trial
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
For patients undergoing TKA for osteoarthritis of the knee joint, pain control will be performed using the same pain control technique (pain control using NSAID) until discharge (1 week after surgery) after surgery. By evaluating the Visual Analogue Scale (VAS), which is known as the patient's pain criterion, the study will be conducted only on patients whose score is more severe than 4 points. Among these subjects, only patients who agreed to the study will be assigned to the group taking duloxetine and the group taking opioids with the same probability according to the randomization table for one week after surgery, that is, upon discharge. In our hospital, almost all patients with total knee arthroplasty are discharged one week after surgery, except for special cases such as morbidity of systemic diseases such as cardiopulmonary dysfunction or acute infection after surgery.
Among the co-researchers, one researcher who is in charge of only patient assignment is selected, and the person in charge creates a randomization table through computer generated randomization. During the assignment process, the assignee will not know in advance the next assignment group, and the randomization table is kept in secret. The assignee does not intervene in any other process of this study, and participates only in the task of selecting the assigned group using random checks. The evaluation is evaluated by an evaluator who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study. Such a study plan will be fully explained to the patient in the process of seeking consent for the study before discharge, as it is recorded in detail in the subject description, and only patients who have obtained this consent will be the subject of the study.
This criterion is established because both duloxetine and opioid are not used for all patients after surgery, but for additional pain control after surgery. Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. In general, if duloxetine is not taken for more than 10 weeks, the frequency of discontinuation syndrome that can occur after discontinuation is remarkably low, so the administration period of 6 weeks was set as the administration period. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Before surgery, 1 week after surgery, 2 weeks, 6 weeks, 3 months, 6 months, 1 year The degree of pain will be measured using the VAS pain scale, WOMAC pain scale, Brief pain inventory (BPI), Intermittent and Constant Osteoarthritis The pain (ICOAP) score is used to measure additional pain scales in various ways. In addition, SF-36 will be measured before surgery, at 6 weeks, 3 months, 6 months, and 1 year after surgery.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults over age 19
- Patients undergoing total knee arthroplasty for osteoarthritis of the knee joint
- Patients with a pain VAS scale of 4 or more out of 10 after TKA with a pain in the knee joint during daily activities on flat ground
- Patients who are willing or able to follow doctor's instructions, including joint exercises
- Patients not participating in other clinical trials
- Patients who have received sufficient explanation for this clinical trial and agreed to participate
Exclusion Criteria:
- Patients with secondary knee osteoarthritis
- Patients with hypersensitivity reactions and serious side effects to duloxetine or opioid
- Patients with inflammatory arthritis or crystalline arthritis
- Local infection to the lower extremities of the pain area, sepsis, or previous neurological abnormalities.
- Patients who underwent meniscus surgery on the knee joint in the painful area
- If there is construction or deformation of the knee joint in the pain area
- Patients with serious heart-related diseases such as cardiac arrest, a history of cerebral infarction, or ischemic heart disease
- Patients with high blood pressure with poor blood pressure control (Systolic Blood Pressure of> 150 mmHg or Diastolic Blood Pressure> 95 mmHg)
- Patients with abnormal liver function (ALT)> 2.0 times the upper limit of normal (ULN) or blood urea nitrogen (BUN) or serum creatinine> 2.0 times ULN)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Experimental: Duloxetine group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine or opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
|
Aktiv komparator: Active comparator: Opioid group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine or opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Visual Analogue Scale
Tidsramme: changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
score ranges 0 to 10, higher score means more painful
|
changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
|
Brief pain inventory (BPI)
Tidsramme: changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
includes 7 categories.
each category score ranges 0 to 10, higher score means more painful
|
changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
WOMAC(Western Ontario and McMaster University Arthritis Index ) pain scale
Tidsramme: changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).
higher score means more painful.
|
changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
|
Intermittent and Constant Osteoarthritis pain (ICOAP) score
Tidsramme: changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
11-item tool that assess pain at knee joint.
The 11 items are scored froma 0 to 4 with 0 being no pain and 4 being extreme pain
|
changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
|
SF-36(Short Form Health Survey - 36) score
Tidsramme: changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
a 36-item, patient-reported survey of patient health.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability
|
changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
|
Range of Motion
Tidsramme: The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
|
The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Postoperative komplikationer
- Smerte
- Neurologiske manifestationer
- Ledsygdomme
- Muskuloskeletale sygdomme
- Reumatiske sygdomme
- Gigt
- Slidgigt
- Smerter, postoperativ
- Slidgigt, knæ
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Psykotropiske stoffer
- Neurotransmitter optagelseshæmmere
- Membrantransportmodulatorer
- Antidepressive midler
- Dopaminmidler
- Serotonin- og Noradrenalin-genoptagelseshæmmere
- Duloxetinhydrochlorid
Andre undersøgelses-id-numre
- KC20MISI0531
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Slidgigt, knæ
-
Smith & Nephew, Inc.Nor Consult, LLCAfsluttetJourney II XR Total Knee SystemForenede Stater
-
Smith & Nephew, Inc.AfsluttetSikkerhed og ydeevne af Journey II BCS Total Knee System Patient rapporterede resultatmål (JIIPROMS)Journey II BCS Total Knee SystemForenede Stater, Belgien, New Zealand
-
Smith & Nephew, Inc.Nor ConsultAfsluttetJourney II CR Total Knee SystemForenede Stater
-
Clinical Center of VojvodinaAktiv, ikke rekrutterendeOsteoarthritisSerbien
-
Gaziler Physical Medicine and Rehabilitation Education...RekrutteringOsteoarthritis | Knæ Arthritis, SlidgigtTyrkiet (Türkiye)
-
Indonesia UniversityAfsluttetKnæ slidgigt | OsteoarthritisIndonesien
-
Assiut UniversityIkke rekrutterer endnu
-
University of KarachiRekrutteringKnæ slidgigt | Knæsmerter Gigt | OsteoarthritisPakistan
-
Kirsehir Ahi Evran UniversitesiIkke rekrutterer endnu
-
Fundació EurecatHISPANAGAR SARekrutteringBetændelse | Bruskskade | Ledskade | OsteoarthritisSpanien
Kliniske forsøg med Duloxetine vs. Opioid
-
Göteborg UniversityIkke rekrutterer endnuSund og raskSverige
-
Verastem, Inc.AfsluttetIkke småcellet lungekræft | KRAS Aktiverende MutationForenede Stater, Spanien, Frankrig, Tyskland, Italien
-
Northwestern UniversityNational Institute on Aging (NIA)AfsluttetKognitiv svækkelse | Alzheimers sygdomForenede Stater
-
Verastem, Inc.GOG Foundation; European Network of Gynaecological Oncological Trial Groups...Aktiv, ikke rekrutterendeLivmoderhalskræft | Lavgradigt ovarie serøst adenokarcinomSpanien, Forenede Stater, Belgien, Det Forenede Kongerige, Frankrig, Canada, Italien
-
University Children's Hospital, ZurichAfsluttetTid indtil identifikation af defineret parameterSchweiz
-
Weill Medical College of Cornell UniversityTrukket tilbage
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)AfsluttetHukommelseskonsolideringForenede Stater
-
Gruppo Italiano Studio LinfomiAfsluttetAvanceret Hodgkins sygdomItalien
-
Penn State UniversityAfsluttetOpførsel, sundhedForenede Stater
-
Verastem, Inc.Japanese Gynecologic Oncology GroupAktiv, ikke rekrutterendeLivmoderhalskræft | Lav grad af serøs ovariecancerJapan